['multiple myeloma']
['plitidepsin', 'bortezomib', 'dexamethasone']

        Inclusion Criteria:

          -  Age ≥ 18 years.

          -  Prior autologous transplantation (HSCT) patients are allowed.

          -  Patients must have received at least one previous treatment line of induction,
             chemotherapy, chemotherapy and transplantation or previous treatment with bortezomib
             or another proteasome drug

        Exclusion Criteria:

          -  Previous treatment with plitidepsin.

          -  Active or metastatic primary malignancy other than MM.

          -  Serious concomitant systemic disorders

          -  History of hypersensitivity reactions to bortezomib, polyoxyl 35 castor oil or
             mannitol

          -  Neuropathy

          -  Pregnant and/or lactating women

          -  HIV infection

          -  Active hepatitis B or C virus infection.

          -  Treatment with any Investigational Medicinal Product (IMP) in the 30 days before
             inclusion in the study

          -  Plasma cell leukemia at the time of study entry

          -  Contraindication for the use of steroids
      